Bristol Myers Says EMA's CHMP Recommended Approval Of Opdivo Combination With Cisplatin, Gemcitabine For First-line Treatment Of Adult Patients With Unresectable Or Metastatic Urothelial Carcinoma
Bristol Myers Says EMA's CHMP Recommended Approval Of Opdivo Combination With Cisplatin, Gemcitabine For First-line Treatment Of Adult Patients With Unresectable Or Metastatic Urothelial Carcinoma
布里斯托爾·邁爾斯說，EMA的CHMP建議批准Opdivo與順鉑、吉西他濱聯合用於不可切除或轉移性尿路上皮癌的成年患者的一線治療
The European Commission (EC), which has the authority to approve medicines for the European Union (EU), will now review the CHMP recommendation. The final EC decision is expected in June 2024.
有權批准歐盟（EU）藥品的歐盟委員會（EC）現在將審查CHMP的建議。歐共體的最終決定預計將在2024年6月作出。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。